

#### Session 11, Evaluating Onsite Healthcare's Impact on Population Health, Healthcare cost, and Workforce Productivity

SOA Antitrust Disclaimer SOA Presentation Disclaimer

# 2019 Health Meeting

#### JOHN DAWSON, GARY WILLIAMS, KUMAR SUBRAMANIAM

Session 011

Evaluating Onsite Healthcare's impact on population health, healthcare cost, and workforce productivity.

June 24, 2019







John Dawson, Chief Actuary and Senior Vice President Healthstat, Inc











healthstat





- Disruptive innovation that brings healthcare closer to the consumer
- Care may be delivered by a physician, physician assistant, or nurse practitioner
- Incentives are commonly used to encourage clinic utilization and engagement

- Onsite dispensary drives utilization and medication compliance.
- Routine labs can be processed on site; some larger clinics offer imaging services
- Scope of services vary widely from one clinic and onsite healthcare provider to the next



#### Behavior Change

# healthstat



#### **Behavior Change**

# healthstat

Relapse



SOCIETY OF ACTUARIES

healthstat



Source: National Association of Worksite Health Centers/Mercer, Worksite Medical Clinics 2018 Survey Report

#### **Measuring Results**

# healthstat









Source: National Association of Worksite Health Centers/Mercer, Worksite Medical Clinics 2018 Survey Report







- The objectives to be measured
- The types of centers used by employers to provide various levels of medical and occupational health services
- The metrics and methodology to be used
- The definitions to be agreed on
- The population to be measured
- The areas to be measured
- The data required and available for use; and
- The types and frequency of the reports for various areas being measured

healthstat

## **Diversion of Care**



This formula may be appropriate for acute care clinics that focus on diverting care into a lower cost setting.

But, this formula applies the **wrong paradigm** for an onsite healthcare program focused on engaging members in reducing risk and improving health.





A more comprehensive approach compares actual claim costs to a baseline to determine claim cost reduction over time.

When coupled with health improvement metrics, this approach can validate an employer's investment in an onsite healthcare program.



#### Gary Williams, Vice President of Human Resources Mount Vernon Mills, Inc.







- Privately owned 100% Domestic Textile Manufacturing Company yes, we still exist!!
- 2,400 Employees 6,200 in 1999
- Close to \$500 Million in Sales
- Operating 12 locations in 5 States South Carolina, North Carolina, Georgia, Alabama, Mississippi





- Average age approaching 50 YOA
- Benefits at a premium
- Competing in a global market with high capitalization and low margin products
- Customers continue to dictate pricing and requirements
- Example of how the "price rollbacks" work





- The challenge for all of us beating the trend!!
- Medical costs continue to increase as margins shrink. (Did I mention that we are a textile company?)
- Total Cost of Health Issues







# Millions of Years











Number 1 driver of escalating Health Care Cost:

The Chronically III – Even worse than the 80/20 rule we have heard.







Average Annual Health Insurance Premiums and Worker Contributions for Family Coverage, 2005–2015



During the same period, workers' wages increased 1.9% and inflation declined 0.2%

SOURCE: Kaiser/HRET Survey of Employer-Sponsored Health Benefits, 2005–2015.





- Managed Care
- Cost Sharing
- Consumer Driven

- Plan Design
- Health Fairs
- Disease Management





- Direct savings on medical costs.
- Allow changes to plan design less painful?
- Time away from work savings.
- Employee satisfaction in a difficult situation

(did I mention we are in the textile industry?)





- Started first clinic in Trion, GA (1500 ee's) in September 2003 voluntary for ee's
- Opened clinics at all other locations on or about July 2004. Eliminated co-pays at physician offices, allowed spouses, & **no fee to see the Nurse Practitioners**
- Required employee participation in Jan. 2005
- Required spouse participation in 2006
- Clinics run from 8 to 36 hours per week depending on plant size
- Required compliance for employees in 2013 spouses required for 2015







#### Healthstat

160 140 120 100 80 60 40 20 0 Diastolic BP Systolic BP Goal Initial Assessment Last Assessment

#### Mount Vernon Mills





#### HEALTHSTAT

MOUNT VERNON MILLS

The change in blood pressure reduced risk of 10-year cardiovascular mortality rate complications by 24% The change in blood pressure reduced risk of 10-year cardiovascular mortality rate complications by 34%









#### HEALTHSTAT

#### MOUNT VERNON MILLS

The change in total cholesterol reduced risk of cardiovascular complications by 20% The change in total cholesterol reduced risk of cardiovascular complications by 22%









Reduced FBG is associated with decreased risk of heart attack and complications of diabetes (retinopathy, kidney disease, peripheral artery disease, and stroke).







- PEPY (Medical & Rx Costs Only Assume 50% Reduction in Healthcare Trend)
- Actual PEPY (Medical & Rx Claim Costs)
- Linear Regression of Actual PEPY (2012-2018)





#### Kumar Subramaniam, DBA, Executive Director, Population Health Analytics Johns Hopkins HealthCare Solutions





Approach







#### Where Population Health Informatics Fits





Population Health Informatics

Source: CPHIT White Paper in JAMIA - Kharrazi H. et. al. https://www.ncbi.nlm.nih.gov/pubmed/27018264











- Outcomes are only as good as the quality completeness, accuracy, consistency, reliability – of the sourced data and methods used.
- Some though not all data relevant to population health are unstructured and "messy" (e.g., clinicians notes and social networks).
- Some data streams (imaging, sensors, genomics) are huge, but most others are reasonably sized (by today's tech standards)
- Until interoperability (both within and external to care delivery) is surmounted, much data will be missing and difficult to link.
- So called "machine learning" / "Al" is only a small part of the solution and often overrated. Logic, evidence and "domain expertise" are still essential.
- Tools to share practical information with humans is key.



#### **Risk Stratification to Inform Intervention**



- Hopkins Healthcare uses predictive models based on claims, labs, and other data sources to identify individuals by risk level
- Resource Utilization Bands (RUB scores), hospitalization risk scores, and other risk scores from the Johns Hopkins ACG System help categorize individuals by level of risk
- Risk-based stratification of populations by risk allows us to identify subgroups for intervention
- Predictive modeling and patient stratification help match patients' health needs to appropriate interventions





#### ACG – A Unique Population Health Analytics Tool





#### A Unique Approach

"Clustering of morbidity is a better predictor of resource use than the presence of a specific disease"

Developed by a Pediatrician -Barbara Starfield and continually maintained by CPHIT team at Johns Hopkins Bloomberg School of Public Health



# Used within JH & Commercially

Used by:

•

- All 4 JHHC LOBs
- Payers
- Providers
- Self-Insured Employers
- Governments
- Integrators
  - The UK, Italy, Spain, South Africa, Norway, Sweden, Germany and many others



#### **Clinically Validated**

Validated in over 20 countries

Used to actively monitor & manage 170+ million lives

Referenced in +/- 900 peer-reviewed journal articles



The ACG System is ...

**Clinically Cogent** 

Flexible & Customizable

A revenue source for JHHC and JHBSPH



# The ACG System uses an integrated set of tools to identify individuals for proactive, targeted interventions







## ACG System – Core Applications and Use Cases



#### Core Applications and Use Cases





Population Segmentation & Risk Stratification



# CONSTITUTE OF PERFORMED Brance Construction Performance Construction of the performance compared in the exercise of the digitation performance of the digitation performance of the digitation of the exercise of the digitation performance of the digitation of the exercise of the exercise of the exercise of the digitation of the exercise of the

What is the current risk of a population or sub-group compared to a benchmark?

What are the specific risk factors that are contributing to resource use?





#### ACG SYSTEM APPROACH

Begin by segmenting the population to understand the current risk of the population compared to the average. Here we see that this patient population's utilization of resources is 50% higher than a comparison group based on their patterns of morbidity.

#### Population

Patient Count	2,062	Average Age	51
Total Cost	\$21,789,386	Local Average Age	46
Pharmacy Cost	\$2,056,048	Local Average Total Cost	\$7,299
Total Cost PMPY	\$10,567	Local Average Pharmacy Cost	\$802
Pharmacy Cost PMPY	\$997	Local Age-Gender Concurrent Risk	1.16
Truncated Patient Cou	nt 0	Local ACG Concurrent Risk	1.48
Truncated Total Cost	\$0		



Understand which risk factors are more present than average

Population Risk Factors 1+ Hospital Dominant Morbidit(ies) Frailty Condition 1+ Chronic Condition(s) Psychosocial Condition

Subgroup	Reference
17.99%	4.76%
5.72%	2.16%
68.57%	49.89%
26.24%	24.61%





SMR is an epidemiological technique where individuals get classified and compared to a reference population, against people of similar age/gender.

This can identify conditions that have a disproportionate prevalence compared to what would be expected in the reference population.

## Disease Prevalence (Top 30 Conditions)

				Age-Sex		
EDC	Description	Patients	Obs/1000	Exp/1000	SMR	Sig
ADM06	Preventive Care	1,307	633.85	503.21	1.26	+
ADM05	Administrative concerns and non-specific laboratory abnormalities	624	302.62	287.43	1.05	
CAR14	Hypertension, w/o major complications	544	263.82	276.67	0.95	
CAR11	Disorders of lipid metabolism	489	237.15	235.79	1.01	
MUS17	Musculoskeletal disorders, other	487	236.18	87.66	2.69	
MUS01	Musculoskeletal signs and symptoms	332	161.01	226.51	0.71	
EAR11	Acute upper respiratory tract infection	251	121.73	131.75	0.92	
NUR01	Neurological signs and symptoms	241	116.88	38.85	3.01	+
	EDC ADM06 ADM05 CAR14 CAR11 MUS17 MUS01 EAR11 NUR01	EDC ADM06Description Preventive CareADM05Administrative concerns and non-specific laboratory abnormalitiesCAR14Hypertension, w/o major complicationsCAR11Disorders of lipid metabolismMUS17Musculoskeletal disorders, otherMUS01Musculoskeletal signs and symptomsEAR11Acute upper respiratory tract infectionNUR01Neurological signs and symptoms	EDC ADM06Description Preventive CarePatients 1,307ADM05Administrative concerns and non-specific laboratory abnormalities624CAR14Hypertension, w/o major complications544CAR11Disorders of lipid metabolism489MUS17Musculoskeletal disorders, other487MUS01Musculoskeletal signs and symptoms332EAR11Acute upper respiratory tract infection251NUR01Neurological signs and symptoms241	EDC ADM06Description Preventive CarePatients 1,307Obs/1000 	EDC ADM06Description Preventive CarePatients 1,307Obs/1000 633.85Exp/1000 633.85ADM05Administrative concerns and non-specific laboratory abnormalities624302.62287.43CAR14Hypertension, w/o major complications544263.82276.67CAR11Disorders of lipid metabolism489237.15235.79MUS17Musculoskeletal disorders, other487236.1887.66MUS01Musculoskeletal signs and symptoms332161.01226.51EAR11Acute upper respiratory tract infection251121.73131.75NUR01Neurological signs and symptoms241116.8838.85	EDC ADM06Description Preventive CarePatients 1,307Obs/1000 633.85Exp/1000 Exp/1000SMR 1.26ADM05Administrative concerns and non-specific laboratory abnormalities624302.62287.431.05CAR14Hypertension, w/o major complications544263.82276.670.95CAR11Disorders of lipid metabolism489237.15235.791.01MUS17Musculoskeletal disorders, other487236.1887.662.69MUS01Musculoskeletal signs and symptoms332161.01226.510.71EAR11Acute upper respiratory tract infection251121.73131.750.92NUR01Neurological signs and symptoms241116.8838.853.01

# Similarly, RxMG prevalence allows us to see which medications are most prevalent compared to what would be expected.

#### RxMG Prevalence (Top 30 Conditions)

				Age-Sex(+)		
RxMG	Description	Patients	Obs/1000	Exp/1000	SMR	Sig
INFx020	Infections / Acute minor	//0	575.42	405.94	0.93	
PAIx040	Pain / Severe Pain	427	207.08	201.77	1.03	
CARx030	Cardiovascular / Hypertension	403	195.44	284.16	0.69	
CARx040	Cardiovascular / Hyperlipidema	334	161.98	215.00	0.75	
PSYx040	Psychiatric / Behavioral / Depression	273	132.40	143.09	0.93	
IFAx030	Inflammatory / Systemic: High Impact	215	104.27	98.58	1.06	
RESx040	Repiratory / Airway Hyperactivity	207	100.39	98.42	1.02	
SKNx020	Skin / Acute and Recurrent	201	97.48	124.47	0.78	
IFAx020	Inflammatory / Systemic: Low Impact	199	96.51	110.42	0.87	
CARx070	Cardiovascular / Edema	193	93.60	144.99	0.65	
PSYx030	Psychiatric / Behavioral / Anxiety	173	83.90	106.73	0.79	
GASx011	Gastrointestinal / Hepatic / Symptoms	172	83.41	68.99	1.21	
GASx060	Gastrointestinal / Hepatic / Peptic Disease	170	82.44	84.33	0.98	





Identify High Risk Patients

e cost and tesource use within the segmented population priate use of the ED, high risk opioid use, and other factors n emergent" ED usage than average.

	Percent 29.21	Age-Sex Adjusted Reference % 25.40	Reference % 28.14	
tentially avoidable				

JOHNS HOPKINS

Which patients are at high risk for a hospitalization event in the next 12 months?

Are there opportunities to save costs by redirecting patients who are using the ED for non-emergency or primary care needs?





#### ACG SYSTEM APPROACH

Look at various risk markers that typically drive cost and resource use within the segmented population at the patient level. These may include inappropriate use of the ED, high risk opioid use, and other factors. For example, this health system has higher "non emergent" ED usage than average.

				Age-Sex	
ED Visit Type	ED Visit Type Description	Visit Count	Percent	Adjusted Reference %	Reference %
NONEMERG	Non-emergent	170	29.21	25.40	28.14
EMERGPC	Emergent, primary care treatable	101	17.35	20.22	22.55
EMEDPA	Emergent, ED needed, potentially avoidable	31	5.33	5.57	4.00
EMEDNPA	Emergent, ED needed, not potentially avoidable	133	22.85	22.61	16.52
INJNOSEV	Injury, non-severe	97	16.67	16.50	20.26
INJSEV	Injury, severe	31	5.33	5.42	4.03
INJSEVIP	Injury, severe and inpatient hospitalization likely		0.17	0.40	0.24
PSYCH	Psychiatric		1.55	1.67	2.08
ALCH	Alcohol use		0.17	0.35	0.54
UNCLASS	Unclassified	8	1.37	1.71	1.42

#### Identify High Risk Patients

Focus on specific patients who are lower cost this year but predicted to be high cost next year (based on a Rank Probability High Total cost >0.4) as well as those at high risk of hospitalization or readmission.

For example, this health system has 65 patients predicted to be high cost next year. They can focus on these high risk patients to understand what's driving that cost risk, identify gaps in medication, and determine likelihood of care coordination issues, so they can make appropriate decisions about the patient's care.

## **Prospective Risk**

Rescaled Total Cost Predicted Risk Rescaled Pharmacy Cost Predicted Risk High Risk Patients651.38High Risk Patient Total Costs\$6,135,4361.31High Risk Patient Pharmacy Costs\$213,430

Identify High Risk Patients



#### Pulling a Comprehensive Patient Clinical Profile Report for each high-risk patient will help identify areas of opportunity to actively manage those patients according to their needs.

% Visits Provided By Majority Source of Care

Care Density Est. Cost Saving Ratio

Care Density Est. Cost Saving

2.28

MID

15%

\$15,000-\$20,000

Care Density Ratio

Care Density Quantile

#### **Comprehensive Patient Clinical Profile Report**

**Dialysis Service** 

Nursing Service

**Cancer Treatment** 

**Psychotherapy Service** 

**Mechanical Ventilation** 

Age	70	Sex	F	
PCP Id	FBAD	Product	НМО	
Prior Costs		Case Complexity		
Total Cost	\$118,246	Chronic Condition Count		8
Rx Cost	0	Active Ingredient Count		0
Resource Utilization Band	5	Frailty Flag		Y
Local ACG Concurrent Risk CSR Adjusted HHS Risk Score	10.08	Frailty Concept(s)	Difficulty in wa Major problems retention or coi	lking, of urine ntrol.
		Frailty Concept Count		2
		Compassionate Allowance Co	nditions	N
Predictive Values		Likelihood of Hospitali	zation	
Rank Probability High Total Cost 0.56		Hospital Dominant Morbidit	y Types	
Predicted Total Cost Range \$50	),000 - \$75,000	Probability Hospital Admissi	on (6 mos)	0.37
Rank Probability High Rx Cost	0.02	Probability Hospital Admissi	on (12 mos)	0.50
Predicted Rx Cost Range \$	61,000 - \$1,250	Probability ICU/CCU Admiss	sion	0.05
High Risk Unexpected Pharmacy	N	Probability injury-related Ad	mission	0.03
Probability of Persistent High Use	r 0.11	Probability long-term Admiss	sion (12+ days)	0.34
		Probability of Readmission		0.42
Utilization		Coordination of Care		
Outpatient Visits	70	Coordination Risk		LCI
ER Visits	5	# Unique Providers Seen		15
Inpatient Admissions w/o birth an	dinjury 3	# Specialty Types Seen		2
Unplanned 30-day Readmission		Generalist Seen		Y
Inpatient Days	21	Generalist Visit Count		14
Major Procedure Performed	Y	Management Visit Count		39

Identify High Risk Patients

JOI	łľ	N	S	ŀ	ł(	)]	PI	(	IN	S	

# **QUESTIONS?**









